1,050 results on '"Moutsopoulos, H. M."'
Search Results
2. Sjögren’s syndrome
3. Antiphospholipid syndrome
4. Therapy of Sjögren’s syndrome
5. Subacute Cutaneous Lupus Erythematosus
6. Sjögren’s Syndrome
7. Antiphospholipid Syndrome
8. Sjögren’s Syndrome : Autoimmune Epithelitis
9. Clinical significance of autoantibodies to Ro/SSA and La/SSB
10. Vasculitis in primary Sjögren’s syndrome
11. Sjögren’s Syndrome: From Polyclonal B Cell Activation to Monoclonal B Cell Proliferation
12. Rheumatoid Arthritis in Southeastern Europe
13. Sjogren’s Syndrome, a Model to Study Autoimmunity and Malignancy
14. SJOGREN'S SYNDROME ASSOCIATED LYMPHOMAS: CLINICAL DESCRIPTION AND 10-YEAR SURVIVAL
15. PREDICTING RISK FACTORS OF MALT LYMPHOMA IN SJOGREN'S SYNDROME
16. SEVERITY OF LABIAL MINOR SALIVARY GLAND FOCUS SCORE AND FUTURE LYMPHOMA DEVELOPMENT IN SJOGREN'S SYNDROME
17. Absence of somatic MYD88 L265P mutations in patients with primary Sjogren’s syndrome
18. OP0294 SJÖGREN’S SYNDROME ASSOCIATED LYMPHOMAS: CLINICAL DESCRIPTION AND 10-YEAR SURVIVAL
19. OP0291 SEVERITY OF LABIAL MINOR SALIVARY GLAND FOCUS SCORE AND FUTURE LYMPHOMA DEVELOPMENT IN SJÖGREN’S SYNDROME
20. POS0290 PREDICTING RISK FACTORS OF MALT LYMPHOMA IN SJÖGREN’S SYNDROME
21. PHENOTYPIC DIFFERENCES BETWEEN SJOGREN'S SYNDROME PATIENTS WITH LOW AND HIGH-GRADE INFLAMMATION BASED ON SALIVARY GLAND FOCUS SCORE
22. THE CLINICAL FEATURES OF SJOGREN'S SYNDROME PATIENTS WITH EARLY AND LATE DISEASE ONSET
23. THE DIFFERENCES BETWEEN SJOGREN'S SYNDROME PATIENTS WITH COMBINED SERONEGATIVITY AND ANTI-RO/SSA SEROPOSITIVITY
24. THE DIFFERENCES IN THE CLINICAL SPECTRUM OF CRYOGLOBULINEMIC VASCULITIS BETWEEN SJOGREN'S SYNDROME AND HCV HEPATITIS
25. Therapy of Sjögren’s syndrome
26. Erythema Nodosum: the Underlying Conditions
27. B-Cell Epitopes of Intracellular Autoantigens: Myth and Reality
28. OP0096 THE DIFFERENCES BETWEEN SJÖGREN’S SYNDROME PATIENTS WITH COMBINED SERONEGATIVITY AND ANTI-RO/SSA SEROPOSITIVITY
29. FRI0149 THE CLINICAL FEATURES OF SJÖGREN’S SYNDROME PATIENTS WITH EARLY AND LATE DISEASE ONSET
30. FRI0161 PHENOTYPIC DIFFERENCES BETWEEN SJÖGREN’S SYNDROME PATIENTS WITH LOW AND HIGH-GRADE INFLAMMATION BASED ON SALIVARY GLAND FOCUS SCORE
31. THU0294 THE DIFFERENCES IN THE CLINICAL SPECTRUM OF CRYOGLOBULINEMIC VASCULITIS BETWEEN SJÖGREN’S SYNDROME AND HCV HEPATITIS
32. Detection of Coronary Artery Lesions and Myocardial Necrosis by Magnetic Resonance in Systemic Necrotizing Vasculitides
33. Thoracoabdominal motion in ankylosing spondylitis: association with standardised clinical measures and response to therapy
34. Stress, coping strategies and social support in patients with primary Sjögren’s syndrome prior to disease onset: a retrospective case–control study
35. Rates of Infiltration by Macrophages and Dendritic Cells and Expression of Interleukin-18 and Interleukin-12 in the Chronic Inflammatory Lesions of Sjögrenʼs Syndrome: Correlation With Certain Features of Immune Hyperactivity and Factors Associated With High Risk of Lymphoma Development
36. Predicting autoimmune congenital heart block: is it feasible and how?
37. Sjögrenʼs Syndrome or Autoimmune Epithelitis?
38. Expression of functional Toll-like receptors by salivary gland epithelial cells: increased mRNA expression in cells derived from patients with primary Sjögrenʼs syndrome
39. Analysis of parotid glands of primary Sjögrenʼs syndrome patients using proteomic technology reveals altered autoantigen composition and novel antigenic targets
40. Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy
41. Sjögrenʼs syndrome: why autoimmune epithelitis?
42. Post-translational modifications of the major linear epitope 169–190aa of Ro60 kDa autoantigen alter the autoantibody binding
43. Long term remission of Sjögren’s syndrome associated aggressive B cell non-Hodgkin’s lymphomas following combined B cell depletion therapy and CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)
44. Preferential recognition of the phosphorylated major linear B-cell epitope of La/SSB 349–368aa by anti-La/SSB autoantibodies from patients with systemic autoimmune diseases
45. Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2β antigen
46. Effect of nandrolone decanoate (Deca-Durabolin) on the disease activity of female patients with systemic lupus erythematosus: A double-blind placebo-controlled study
47. In lupus nephritis, the benefit of rituximab monotherapy, as opposed to rituximab plus cyclophosphamide combination therapy, remains uncertain: Comment on the article by Sfikakis et al
48. Cross-reaction between antibodies to the major epitope of Ro60 kD autoantigen and a homologous peptide of Coxsackie virus 2B protein
49. Impaired elastic properties of ascending aorta in patients with giant cell arteritis
50. How long should we wait for response to iv cyclophosphamide pulse therapy for lupus nephritis?: 167
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.